SCHEMBL2120045

SCHEMBL2120045

Cc1cccc(N(C(C)c2ccccc2F)S(=O)(=O)c2cc(F)ccc2C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 2/20 0.40
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
TP53 P04637 2/20 0.36
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PKM P14618 1/20 0.35
KCNJ6 P48051 2/20 0.35
KCNJ5 P48544 2/20 0.35
KCNJ3 P48549 2/20 0.35
PSEN1 P49768 3/20 0.35
PSEN2 P49810 3/20 0.35
APH1B Q8WW43 3/20 0.35
NCSTN Q92542 3/20 0.35
APH1A Q96BI3 3/20 0.35
PSENEN Q9NZ42 3/20 0.35
HSD11B1 P28845 2/20 0.33
LMNA P02545 1/20 0.33
RAB9A P51151 1/20 0.33
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118908 0.91 TSHR (0.48) RECQLTSHRMAPK1TP53MAPT
SCHEMBL10249846 0.90 HSD11B1 (0.42) RECQLTSHRMAPK1TP53MAPT
SCHEMBL2117856 0.87 RECQL (0.46) RECQLTP53MAPTSMN1; SMN2HSD11B1
SCHEMBL2119849 0.76 HSD11B1 (0.50) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2119805 0.76 SMN1; SMN2 (0.42) TSHRMAPK1MAPTSMN1; SMN2KCNJ6
SCHEMBL2120059 0.73 PSEN1 (0.44) TSHRMAPK1MAPTSMN1; SMN2PSEN1
SCHEMBL2117553 0.66 HSD11B1 (0.44) TSHRMAPK1TP53MAPTSMN1; SMN2
SCHEMBL2120075 0.65 PSEN1 (0.44) MAPK1MAPTSMN1; SMN2PSEN1PSEN2
SCHEMBL2119628 0.64 PSEN1 (0.52) MAPTPSEN1PSEN2APH1BNCSTN
SCHEMBL14443241 0.64 MEP1B (0.45) TSHRMAPK1SMN1; SMN2KCNJ6KCNJ5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 RECQL 4671/4885TSHR 1240/4885MAPK1 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.